Recent Advances in Immunotherapy for Hepatocellular Carcinoma.
Ontology highlight
ABSTRACT: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since most patients are diagnosed at advanced stage and the current systemic treatment options using molecular-targeted drugs remain unsatisfactory. However, the recent success of cancer immunotherapies has revolutionized the landscape of cancer therapy. Since HCC is characterized by metachronous multicentric occurrence, immunotherapies that induce systemic and durable responses could be an appealing treatment option. Despite the suppressive milieu of the liver and tumor immunosurveillance escape mechanisms, clinical studies of checkpoint inhibitors in patients with advanced HCC have yielded promising results. Here, we provide an update on recent advances in HCC immunotherapies. First, we describe the uniqu
SUBMITTER: Nakano S
PROVIDER: S-EPMC7226090 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA